Improving Brain Metastases Outcomes Through SRS and Targeted Therapies

Moffitt Cancer Center’s Neuro-Oncology multidisciplinary team of experts, Drs. Daniel Oliver, Nam Tran, Michael Vogelbaum, Peter Forsyth, Michael Yu, Kamran Ahmed, and Arnold Etame co-authored a publication entitled, “Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies.”

Brain metastases are the most common form of brain cancer. Increasing knowledge of primary tumor biology, actionable molecular targets and continued improvements in systemic and radiotherapy regimens have helped improve survival but necessitate multidisciplinary collaboration between neurosurgical, medical and radiation oncologists. In this publication, they explored the advances of targeted therapies to date and discussed the findings of studies investigating the synergy between these therapies and stereotactic radiosurgery for non-small cell lung cancer, breast cancer, melanoma and renal cell carcinoma brain metastases.

Back in 2022, we sat down with Dr. Michael Vogelbaum, Program Leader of the Neuro-Oncology Department and Chief of Neurosurgery, to discuss stereotactic radiosurgery for brain tumors. Some of the Q&As include:

• What is stereotactic surgery and how is it different from radiation therapy?
• When is stereotactic radiosurgery used?
• Does the use of stereotactic radiosurgery involve a collaborative team of experts?
• What are you excited about in terms of emerging therapies for brain tumors or brain metastasis?

Read the full interview.

To refer a patient to Moffitt for stereotactic radiosurgery and other advanced brain tumor treatment options, complete our online form or contact a physician liaison for assistance or support. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.